secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rezolute, Inc. (RZLT)
CIK:        0001509261
Form:       8-K
Filed at:   2025-02-12T23:59:59+00:00
Accession:  0001104659-25-012173
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rezolute reports Q2 net loss $15.7M; ersodetug gets Breakthrough Therapy, Orphan Drug status
--------------------------------------------------------------------------------

- Cash & equivalents $105.3M at Dec 31, 2024 vs $127.1M at June 30, 2024.
- Net loss $15.7M for Q2 fiscal 2025 vs $13.9M for same period last year.
- FDA granted Breakthrough Therapy Designation for ersodetug in congenital hyperinsulinism (HI).
- FDA granted Orphan Drug Designation for ersodetug in tumor HI.
- Phase 3 sunRIZE study interim analysis planned this quarter; topline results expected Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509261/000110465925012173/0001104659-25-012173-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509261/000110465925012173/tm255593d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-012173

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer